Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 13/20 | 1.00 |
| ▸ | ICOSLG | O75144 | 10/20 | 1.00 |
| ▸ | ICOS | Q9Y6W8 | 10/20 | 1.00 |
| ▸ | IKBKB | O14920 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 1/20 | 1.00 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 1.00 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359984 | 1.00 | CHUK (1.00) | CHUKICOSLGICOSIKBKBMEN1 | |
| Hydrochloric Acid SCHEMBL12471533 | 0.99 | CHUK (0.98) | CHUKICOSLGICOSIKBKBMEN1 | |
| SCHEMBL14253037 | 0.92 | CHUK (1.00) | CHUKICOSLGICOSIKBKBMEN1 | |
| SCHEMBL13377038 | 0.90 | CHUK (1.00) | CHUKICOSLGICOSIKBKBMEN1 | |
| SCHEMBL13376959 | 0.89 | CHUK (0.89) | CHUKICOSLGICOSIKBKBMEN1 | |
| SCHEMBL8378079 | 0.88 | CHUK (0.78) | CHUKICOSLGICOSIKBKBMEN1 | |
| SCHEMBL2768947 | 0.87 | CHUK (0.78) | CHUKICOSLGICOSIKBKBMEN1 | |
| SCHEMBL14253078 | 0.86 | CHUK (0.83) | CHUKICOSLGICOSIKBKBMEN1 | |
| SCHEMBL14253005 | 0.86 | CHUK (0.83) | CHUKICOSLGICOSIKBKBMEN1 | |
| SCHEMBL14253081 | 0.85 | CHUK (0.75) | CHUKICOSLGICOSIKBKBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744141-B2 | Compositions and methods for treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-08-18 | — | — | US | claimed |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | claimed |
| EP-3313819-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Case Western Reserve University (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210134-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-9248124-B2 | Use of inhibitors of IκB kinase for the treatment of cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | claimed |
| WO-2013052844-A1 | METHODS FOR TREATING AND DIAGNOSING RESPIRATORY TRACT INFECTIONS | PULMATRIX, INC. (US) | 2013-04-11 | — | — | WO | claimed |
| EP-1443927-B1 | CARBOLINE DERIVATIVES AS INHIBITORS OF IKB IN THE TREATMENT OF MULTIPLE MYELOMA | MILLENNIUM PHARM INC (US) | 2007-01-10 | — | — | EP | claimed |
| US-20050049265-A1 | Including multiple myeloma; I kappa B [i$g(k)b] kinase | MILLENNIUM PHARMACEUTICALS, INC (US) | 2005-03-03 | — | — | US | claimed |
| EP-1443927-A2 | CARBOLINE DERIVATIVES AS INHIBITORS OF IKB IN THE TREATMENT OF MULTIPLE MYELOMA AND OTHER CANCERS | Millennium Pharmaceuticals, Inc. (US) | 2004-08-11 | — | — | EP | claimed |
| WO-2003039545-A2 | CARBOLINE DERIVATIVES AS INHIBITORS OF IKB IN THE TREATMENT OF MULTIPLE MYELOMA AND OTHERS CANCERS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023118005-A1 | COMPOSITION CONTAINING THE COMBINATION OF A C-GLYCOSIDE AND ESCIN FOR THE CARE OF THE EYE AREA | L'OREAL (FR) | 2023-06-29 | — | — | WO | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| WO-2003039545-A2 | CARBOLINE DERIVATIVES AS INHIBITORS OF IKB IN THE TREATMENT OF MULTIPLE MYELOMA AND OTHERS CANCERS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1268477-A1 | SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-20020099068-A1 | Substituted beta carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-07-25 | — | — | US | disclosed |
| EP-1209158-A1 | Substituted beta-carbolines | Aventis Pharma Deutschland GmbH (DE) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001068648-A1 | SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049265-A1 | Including multiple myeloma; I kappa B [i$g(k)b] kinase | IKBKE, IKBKB, IKBKG | CHUK 5/4885ICOSLG 2722/4885ICOS 2443/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | CHUK 1087/4885ICOSLG 123/4885ICOS 133/4885 |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PPP2CA, PPP3CA, PPP4C | CHUK 848/4885ICOSLG 4701/4885ICOS 4250/4885 |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | CHUK 1087/4885ICOSLG 123/4885ICOS 133/4885 |
| US-10744141-B2 | Compositions and methods for treating cancer | PPP2CA, PPP3CA, PPP4C | CHUK 848/4885ICOSLG 4701/4885ICOS 4250/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | CHUK 1087/4885ICOSLG 123/4885ICOS 133/4885 |
| US-20020099068-A1 | Substituted beta carbolines | CSNK1A1, CSNK2A1, CSNK2B | CHUK 52/4885ICOSLG 4842/4885ICOS 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.